Toggle menu


Start date:
24th March 2020
Co-ordinated by:
University of Sheffield
Main trial site:
Royal Infirmary of Edinburgh, Western General Hospital, St John's Hospital

Existing research raises concern about the accuracy and use of current triage tools used to predict adverse outcomes in pandemics. The PRIEST  study will evaluate current triage methods used to determine if a patient with suspected COVID-19 is to be admitted to hospital or not and whether or not they should be admitted to ICU/HDU. Based on the information collected from this study, two new triage tools will be created. The first will include clinical characteristics alone, and will be used in the community setting to determine if a full hospital assessment is required. The second would be used in emergency departments to determine if hospital admission is required and will include presenting clinical characteristics and investigations (ECG , chest X-ray and blood results). These new triage tools will be evaluated based upon ability to predict adverse outcomes; patient death or requirement for cardiac, renal or respiratory support.

Local PI

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

Research Team

Polly Black

Senior Research Nurse

Alison Glover

Lead Research Nurse (BTS)

Julia Grahamslaw

Lead Research Nurse

Emma Moatt

Research Project Manager

Fraser Craig

Clinical Trial Assistant

Nicholas Fethers

Research Administrator

More EMERGE Trials

TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.

Read more


Early diagnosis is central to improving outcomes for patients with cancer. For cancers without specific risk factors, or with no screening programs are difficult to diagnose and patients often present with non-specific symptoms. Unfortunately this means that these patients are often diagnosed late on in the development of the disease and treatment options are reduced.

Read more


Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more


Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)